IRVING, Texas and PHOENIX, May 28, 2009 (GLOBE NEWSWIRE) -- Caris Diagnostics (Caris Dx), a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology, announced today that it has expanded its Target GI Colon(sm) tumor testing panel for colorectal cancer (CRC) patients to include BRAF mutation analysis. With the expansion, Target GI Colon(sm) is now one of the most comprehensive colorectal testing panels available, leading to better, more effective therapeutic choices for colon cancer patients.
